NanoSmart's drug delivery system uses human autoimmune antibodies that target many different types of tumors and combined with approved cancer drugs, offers the potential to create a broad range of next-generation, safer, and more effective cancer drug products.
"We are very excited to work closely with Dr. Noah Federman and his colleagues at UCLA, as they will provide access to an extraordinary level of research, development and clinical resources," said Dr. James Smith, president of NanoSmart Pharmaceuticals. "Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products."
"Despite the extensive research into new drug formulations, the pace of advancing benefit to this patient population is unfortunately slowing," said Dr. Noah Federman, director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, a part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center; and Assistant Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA. "We are pleased to collaborate with NanoSmart to help drive the development of these much-needed products."